Sputum Mycobacterium Tuberculosis MRNA As a Marker of Bacteriologic Clearance in Response to Antituberculosis Therapy

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2009 Nov 20

PMID 19923475

Citations 22

Authors

L Li

C S Mahan

M Palaci

L Horter

L Loeffelholz

J L Johnson

R Dietze

S M Debanne

M L Joloba

A Okwera

W H Boom

K D Eisenach

Affiliations

Soon will be listed here.

Abstract

mRNA is a marker of cell viability. Quantifying Mycobacterium tuberculosis mRNA in sputum is a promising tool for monitoring response to antituberculosis therapy and evaluating the efficacy of individual drugs. mRNA levels were measured in sputum specimens from patients with tuberculosis (TB) receiving monotherapy in an early bactericidal activity study of fluoroquinolones and in those receiving a standard rifampin-based regimen in an interleukin-2 (IL-2) trial. In the early bactericidal activity study, sputum for quantitative culture and mRNA analysis was collected for 2 days before and daily during 7 days of study drug administration. In the IL-2 trial, sputum was collected for quantitative culture, Bactec 460 liquid culture, and mRNA analysis throughout the intensive treatment phase. RNA was isolated from digested sputum and tested in quantitative reverse transcription-PCR assays for several gene targets. mRNA for the glyoxylate cycle enzyme isocitrate lyase declined at similar rates in patients receiving isoniazid, gatifloxicin, levofloxacin, and moxifloxacin monotherapy. Isocitrate lyase mRNA correlated highly with CFU in sputum prior to therapy and during 7 days of monotherapy in all treatment arms. Isocitrate lyase mRNA was detectable in sputum of culture-positive TB patients receiving a rifampin-based regimen for 1 month. At 2 months, sputum for isocitrate mRNA correlated more closely with growth in liquid culture than did growth on solid culture medium. Data suggest that isocitrate lyase mRNA is a reliable marker of M. tuberculosis viability.

Citing Articles

New Insights into Biomarkers for Evaluating Therapy Efficacy in Pulmonary Tuberculosis: A Narrative Review.

Zhang F, Zhang F, Dong Y, Li L, Pang Y Infect Dis Ther. 2023; 12(12):2665-2689.

PMID: 37938418 PMC: 10746651. DOI: 10.1007/s40121-023-00887-x.

An optimized method for purifying, detecting and quantifying Mycobacterium tuberculosis RNA from sputum for monitoring treatment response in TB patients.

Zainabadi K, Lee M, Walsh K, Vilbrun S, Mathurin L, Ocheretina O Sci Rep. 2022; 12(1):17382.

PMID: 36253384 PMC: 9574834. DOI: 10.1038/s41598-022-19985-w.

The impact of complex in the environment on one health approach.

Zhang H, Liu M, Fan W, Sun S, Fan X Front Public Health. 2022; 10:994745.

PMID: 36159313 PMC: 9489838. DOI: 10.3389/fpubh.2022.994745.

Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans.

Van Wijk R, Hu W, Dijkema S, van den Berg D, Liu J, Bahi R Br J Pharmacol. 2020; 177(24):5518-5533.

PMID: 32860631 PMC: 7707096. DOI: 10.1111/bph.15247.

Detection, survival and infectious potential of in the environment: a review of the evidence and epidemiological implications.

Martinez L, Verma R, Croda J, Horsburgh Jr C, Walter K, Degner N Eur Respir J. 2019; 53(6).

PMID: 31048345 PMC: 6753378. DOI: 10.1183/13993003.02302-2018.

References

Moore D, Curry J, KNOTT C, JONAS V . Amplification of rRNA for assessment of treatment response of pulmonary tuberculosis patients during antimicrobial therapy. J Clin Microbiol. 1996; 34(7):1745-9. PMC: 229106. DOI: 10.1128/JCM.34.7.1745-1749.1996. View

Johnson J, Hadad D, Boom W, Daley C, Peloquin C, Eisenach K . Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006; 10(6):605-12. View

Timm J, Post F, Bekker L, Walther G, Wainwright H, Manganelli R . Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci U S A. 2003; 100(24):14321-6. PMC: 283590. DOI: 10.1073/pnas.2436197100. View

Wallis R, Vinhas S, Johnson J, Ribeiro F, Palaci M, Peres R . Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis. 2003; 187(2):270-8. DOI: 10.1086/346053. View

Donald P, Sirgel F, Venter A, Parkin D, Seifart H, van de Wal B . Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther. 2004; 1(1):141-55. DOI: 10.1586/14787210.1.1.141. View

Gamboa F, Manterola J, Lonca J, Vinado B, Matas L, Gimenez M . Rapid detection of Mycobacterium tuberculosis in respiratory specimens, blood and other non-respiratory specimens by amplification of rRNA. Int J Tuberc Lung Dis. 1998; 1(6):542-55. View

Johnson J, Ssekasanvu E, Okwera A, Mayanja H, Hirsch C, Nakibali J . Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003; 168(2):185-91. DOI: 10.1164/rccm.200211-1359OC. View

Yuan Y, Crane D, Simpson R, Zhu Y, Hickey M, Sherman D . The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci U S A. 1998; 95(16):9578-83. PMC: 21381. DOI: 10.1073/pnas.95.16.9578. View

Menendez M, Garcia M, Navarro M, Gonzalez-Y-Merchand J, Rivera-Gutierrez S, Garcia-Sanchez L . Characterization of an rRNA operon (rrnB) of Mycobacterium fortuitum and other mycobacterial species: implications for the classification of mycobacteria. J Bacteriol. 2002; 184(4):1078-88. PMC: 134815. DOI: 10.1128/jb.184.4.1078-1088.2002. View

10.

Ribeiro-Rodrigues R, Co T, Johnson J, Ribeiro F, Palaci M, Sa R . Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin Diagn Lab Immunol. 2002; 9(4):818-23. PMC: 120011. DOI: 10.1128/cdli.9.4.818-823.2002. View

11.

Hellyer T, Desjardin L, Hehman G, Cave M, Eisenach K . Quantitative analysis of mRNA as a marker for viability of Mycobacterium tuberculosis. J Clin Microbiol. 1999; 37(2):290-5. PMC: 84288. DOI: 10.1128/JCM.37.2.290-295.1999. View

12.

Desjardin L, Perkins M, Wolski K, Haun S, Teixeira L, Chen Y . Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med. 1999; 160(1):203-10. DOI: 10.1164/ajrccm.160.1.9811006. View

13.

Mitchison D . Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis. 1993; 147(4):1062-3. DOI: 10.1164/ajrccm/147.4.1062. View

14.

Dietze R, Teixeira L, Rocha L, Palaci M, Johnson J, Wells C . Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2001; 45(7):1972-6. PMC: 90587. DOI: 10.1128/AAC.45.7.1972-1976.2001. View

15.

Nunez M, Menendez M, Rebollo M, Garcia M . Transcriptional analysis of Mycobacterium fortuitum cultures upon hydrogen peroxide treatment using the novel standard rrnA-P1. BMC Microbiol. 2008; 8:100. PMC: 2443159. DOI: 10.1186/1471-2180-8-100. View

16.

Desjardin L, Hayes L, Sohaskey C, Wayne L, Eisenach K . Microaerophilic induction of the alpha-crystallin chaperone protein homologue (hspX) mRNA of Mycobacterium tuberculosis. J Bacteriol. 2001; 183(18):5311-6. PMC: 95413. DOI: 10.1128/JB.183.18.5311-5316.2001. View

17.

Erol A . Visceral adipose tissue specific persistence of Mycobacterium tuberculosis may be reason for the metabolic syndrome. Med Hypotheses. 2008; 71(2):222-8. DOI: 10.1016/j.mehy.2008.03.028. View

18.

Hellyer T, Desjardin L, Assaf M, Bates J, Cave M, Eisenach K . Specificity of IS6110-based amplification assays for Mycobacterium tuberculosis complex. J Clin Microbiol. 1996; 34(11):2843-6. PMC: 229418. DOI: 10.1128/jcm.34.11.2843-2846.1996. View